Job Alert: Microbiology Applications Engineer

ACORN CONSULTING

Job Title: AA Microbiology Applications Engineer Job Status: exempt Full Time / Exempt
 
General Description:  Work based in Tucson, AZ
To serve as a bridge between product development and sales by developing, supporting and representing the Company’s technology in an industrial environment, through use of knowledge of engineering and programming as well as sophisticated instruments and computers.

To identify customer best fit with Company’s product & assist in development of technical documents and training programs, maintaining customer cGMP compliance.       To work independently and as a team player on simultaneous projects with compressed timelines; traveling up to 50% of the time interfacing with customers and attending or exhibiting at conferences and trade shows.

 

Responsibilities:
Product development engineering support for both hardware and software technologies to support real time microbial detection and analysis.

  • Develop and support lab activities and practices for development validation, manufacturing and field demonstration/installation
  • Plan, design, collect and report test goals, technology, information and data
  • Applies commonly-used concepts, practices and procedures within the biological laboratory to company activities.
  • Assist in the design, development and validation of company technology including hardware and software.
  • Prepare and present notes, reports & literature as required
  • Works within and ensures all team members follow safety, FDA, IS0 9001 requirements
  • Consistency with customer cGMP/cGLP compliance as required
  • Provide demonstrations and training of technology and functionality to potential customers and collaborators.

Customer relations

  • Support instrument and technology functionality and capability to both customers and sales force.
  • Act as the primary technical support contact for customers both pre and post installation or demonstration.
  • Provide feedback to the organization relating insights, requests and opportunities from sales, marketing, and customer interactions.
  • Prepare and present technical presentations and applications notes.
  • Professional representation of the company in various field activities including conferences, trade shows, customer site visits and investor visits.

 

Preferred Qualifications:
BA/BS or MS in biological discipline with at least two years work-related experience. Practical experience in industrial/R&D lab environment with focus toward microbiology. Experience with laboratory instrumentation, technology and tools. Self-motivated with a strong work ethic; independently or as part of a team. Strong written and oral communication skills. Good computer skills; minimum of Word, Excel, Power Point with NI LabView experience preferred. Knowledge of or experience with cGLP or cGMP environment. Competitive salary and benefits commensurate with experience.

To Apply:

Send your cover letter and resume to davidbrownwilson@gmail.com. No calls please.

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Pediatric Schizophrenia

PHOENIX, AZ, Nov 24, 2014 (Marketwired via COMTEX) — Insys Therapeutics, Inc. INSY, +0.44% a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company’s CBD program.Continue reading

ASU’s Project Honey Bee paired up with DCU’s MedEx

The transatlantic flight of Project HoneyBee

honey bee

Inspired by the honeybee, nature’s best collector and communicator of information, Project HoneyBee seeks to validate wearable sensor data in order to improve patient outcomes.
Photo by: “Apis mellifera flying” by Muhammad Mahdi Karim
Another transformative collaboration has emerged from the Transatlantic Higher Education Partnership between Arizona State University and Dublin City University – the launch of Project HoneyBee.

In conjunction with its successful MedEx Wellness Program, Dublin City University (DCU) has signed on to launch a Project HoneyBee observational clinical trial. MedEx is a chronic illness rehabilitation program that offers medically designed and supervised exercise classes to patients with diverse chronic illnesses.

As part of the HoneyBee collaboration, medical director, Noel McCaffrey, will incorporate methods from Mayo Clinic physician and ASU professor James Levine’s feasibility study for physical monitoring of diabetes patients into MedEx’s Diabetes Health Steps program.

“We’re excited to test the HoneyBee approach with our MedEx participants. We believe by leveraging technology, we can improve their health outcomes dramatically,” said Christine Loscher, director of health technologies at DCU.

Inspired by the honeybee, nature’s best collector and communicator of information, Project HoneyBee seeks to validate wearable sensor data in order to improve patient outcomes. Since its inception, the initiative has partnered with the health systems in Maricopa County, creating a living laboratory for evaluating the clinical utility of wearable devices to improve health outcomes.

HoneyBee’s eight ongoing observational clinical trials currently test 10 different devices for particular physiological parameters. Each trial has 25 to 50 patients. The overarching goal is to help shift health practitioners’ focus to cost-effective and outcome-effective prevention and early intervention strategies. A critical element of these studies is validating data from low-cost consumer wearable technologies for applications in clinical settings.

Lee Hartwell, HoneyBee’s chief scientist at the ASU Biodesign Institute’s Center for Sustainable Health, said, “We’re very interested in how Project HoneyBee will work in DCU’s context. We hope to learn from and collaborate with each other in our quest for efficient, effective solutions that deliver better health outcomes.”

One of the key differences between HoneyBee observational clinical trials in Arizona versus the trial in Dublin will be the context within which the devices are being tested, as well as the health care providers engaged in the study. In Dublin, third-year lifestyle intervention students will be embedded in the trial; in Arizona, doctoral nurse practitioners serve as research fellows.

“This is a fantastic opportunity to see how the Project HoneyBee model can be replicated in Europe, along with similar efforts underway in Asia,” said Michael Birt, director of HoneyBee.

This latest announcement is another major collaboration between the two universities, and came during the recent DCU visit to ASU. The other major initiatives include establishing the world’s first International School of Biomedical Diagnostics, creating a Biodesign Europe (modeled on ASU’s Biodesign Institute and delivering a combined effort toward 21st-century health care solutions) and the development of a joint program in student entrepreneurship that will inspire a global perspective.

(480) 727-0369
Biodesign Institute

New Autism Study Safety Data to be Presented at the Translational Neuroscience Cell Symposium

Cord Blood Registry® (CBR®) announced today that Dr. Michael G. Chez principal investigator at Sutter Neuroscience Institute will present data from the first ever FDA-registered study on the safety of autologous umbilical cord blood (AUCB) stem cells in treating autism at the Translational Neuroscience: Bridging the Gap Between Basic Research Discoveries and Clinical Applications Cell Symposium on November 14 2014 in Arlington Virginia.Continue reading